Log In
Print
BCIQ
Print
Print this Print this
 

ARN-509, JNJ56021927

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionSecond-generation androgen receptor antagonist
Molecular Target Androgen receptor
Mechanism of ActionAndrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC); Treat non-metastatic castration-resistant prostate cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today